ATC Group: D06BX01 Metronidazole

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of D06BX01 in the ATC hierarchy

Level Code Title
1 D Dermatologicals
2 D06 Antibiotics and chemotherapeutics for dermatological use
3 D06B Chemotherapeutics for topical use
4 D06BX Other chemotherapeutics
5 D06BX01 Metronidazole

Active ingredients in D06BX01

Active Ingredient Description

Metronidazole is an anti-infectious drug belonging to the pharmacotherapeutic group of nitroimidazole derivatives, which have effect mainly on strict anaerobes. This effect is probably caused by interaction with DNS and different metabolites.

Related product monographs

Title Information Source Document Type  
METROGEL Gel FDA, National Drug Code (US) MPI, US: SPL/PLR
METROSA Gel European Medicines Agency (EU) MPI, EU: SmPC
ROSICED Cream Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ROZEX Cream Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

Malta (MT)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.